Zeelab Pharmacy expands healthcare offerings beyond generic medicines
Zeelab Pharmacy, a health tech company founded in 2018, has grown from a generic medicines provider to a broader healthcare products business. According to Inc42, the company reported revenue exceeding ₹461.3 Cr for FY24.
Editor, Lazyfounder
What Zeelab Pharmacy does
Zeelab Pharmacy, operated by Zee Laboratories Limited, was founded in 2018 and focuses on the health tech sector. The company initially specialized in generic medicines but has since expanded its product range to include a variety of healthcare products, according to Inc42.
Financial performance
Inc42 reports that Zeelab Pharmacy’s revenue for FY24 exceeded ₹461.3 Cr. The platform sources its financial data from public records, statutory filings, and proprietary research, though it advises readers to verify details independently.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
Zeelab Pharmacy’s expansion beyond generics signals growth in India’s health tech sector, particularly in the direct-to-consumer and broader healthcare markets. For founders and operators, this highlights opportunities to diversify product lines in regulated industries, where revenue growth can attract investor interest. The reported financials also serve as a benchmark for peers evaluating their own performance in this space.
Sources
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.
